PALbociclib CoLlaborative Adjuvant Study
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- 4600
Summary
- Conditions
- Breast Cancer
- Type
- Interventional
- Phase
- Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT02513394
- Collaborators
- Austrian Breast & Colorectal Cancer Study Group
- NSABP Foundation Inc
- PrECOG, LLC.
- Breast International Group
- Pfizer
- Investigators
- Principal Investigator: Monica Bertagnolli, MD Alliance Foundation Trials, LLC. Principal Investigator: Erica Mayer, MD Dana-Farber Cancer Institute Principal Investigator: Angela DeMichele, MD University of Pennsylvania Principal Investigator: Michael Gnant, MD ABCSG, Medical University Vienna